Search

Home > Diabetes Knowledge into Practice Podcast > Upcoming and developmental therapeutics in type 2 diabetes
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Upcoming and developmental therapeutics in type 2 diabetes
Category: Health
Duration: 00:13:40
Publish Date: 2020-10-27 05:00:00
Description:

Following the new data and developments presented at recent congresses, we thought it would be a good idea to recap on developmental therapeutics and their predicted role in type 2 diabetes management. This episode focuses on the once-weekly basal insulin icodec, the GIP/GLP-1 agonist tirzepatide and the novel oral antihyperglycaemic agent imeglimin.

Joining us this week to discuss these novel developments is Dr Athena Philis-Tsimikas, Corporate Vice President of the Scripps Whittier Diabetes Institute at Scripps Health and the Director of Community Engagement at Scripps Research Translational Institute in San Diego, California.

References:

- Bajaj H, et al. Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with type 2 diabetes inadequately controlled on OADs and basal insulin. Poster 657, presented at: EASD 2020

- Hövelmann U, et al. Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes. Poster 656, presented at: EASD 2020

- Lingvay I, et al. Effect of three different titration algorithms of insulin icodec vs insulin glargine U100 on time in range in patients with type 2 diabetes inadequately controlled on OADs. Poster 658, presented at: EASD 2020

- Dubourg J, et al. Efficacy and safety of imeglimin in combination with insulin in Japanese patients with type 2 diabetes: results of TIMES 3 trial. Poster 637, presented at: EASD 2020

- Pirro V, et al. Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes. Oral Presentation 146, presented at: EASD 2020

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education
Total Play: 0